Abstract
Structure-based rational design has been considered as a promising approach to design novel proteins. For this purpose, we designed artificial anticoagulant proteins that are able to target Factor Xa (FXa) using a functional motifgrafting approach. The motif corresponded to the residues Cys15 to Cys42 of Ancylostoma caninum anticoagulant peptide 5 (AcAP5), a potent FXa inhibitor. By screening of the Protein Data Bank (PDB) using Vector Alignment Search Tool (VAST, search for three-dimensional scaffolds in protein structures), we screened scaffolds as hosts to reproduce the functional topology of this motif. Three designed artificial chimeric proteins were expressed and purified to test their FXainhibiting ability. One of the recombinant proteins, pep3, was found to inhibit FXa with strong activity (IC50 of 152 nM) in vitro. Moreover, pep3 inhibited arterial thrombosis formation in rats with uniform potency compared with natural AcAP5. Therefore, our data demonstrate that motif-grafting is a useful tool to engineer novel artificial anticoagulant proteins.
Keywords: AcAP5, anticoagulant, Factor Xa, inhibitor, motif-grafting, VAST.
Protein & Peptide Letters
Title:Engineering Novel Anticoagulant Proteins by Motif Grafting
Volume: 21 Issue: 2
Author(s): Yuanjun Zhu, Aihua Liu, Xiaoyan Liu and Yinye Wang
Affiliation:
Keywords: AcAP5, anticoagulant, Factor Xa, inhibitor, motif-grafting, VAST.
Abstract: Structure-based rational design has been considered as a promising approach to design novel proteins. For this purpose, we designed artificial anticoagulant proteins that are able to target Factor Xa (FXa) using a functional motifgrafting approach. The motif corresponded to the residues Cys15 to Cys42 of Ancylostoma caninum anticoagulant peptide 5 (AcAP5), a potent FXa inhibitor. By screening of the Protein Data Bank (PDB) using Vector Alignment Search Tool (VAST, search for three-dimensional scaffolds in protein structures), we screened scaffolds as hosts to reproduce the functional topology of this motif. Three designed artificial chimeric proteins were expressed and purified to test their FXainhibiting ability. One of the recombinant proteins, pep3, was found to inhibit FXa with strong activity (IC50 of 152 nM) in vitro. Moreover, pep3 inhibited arterial thrombosis formation in rats with uniform potency compared with natural AcAP5. Therefore, our data demonstrate that motif-grafting is a useful tool to engineer novel artificial anticoagulant proteins.
Export Options
About this article
Cite this article as:
Zhu Yuanjun, Liu Aihua, Liu Xiaoyan and Wang Yinye, Engineering Novel Anticoagulant Proteins by Motif Grafting, Protein & Peptide Letters 2014; 21 (2) . https://dx.doi.org/10.2174/092986652102131226112049
DOI https://dx.doi.org/10.2174/092986652102131226112049 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanomedicine: Magnetic Nanoparticles and their Biomedical Applications
Current Medicinal Chemistry AMPA Receptor Antagonists as Potential Anticonvulsant Drugs
Current Topics in Medicinal Chemistry Novel Coronavirus 2019 Outbreak: A Global Epidemic
Letters in Drug Design & Discovery Optical Chemical Biosensors for High Throughput Screening of Drugs
Combinatorial Chemistry & High Throughput Screening Interleukin-6 Blockers Improve Inflammation-Induced Lipid Metabolism Impairments but Induce Liver Fibrosis in Collagen-Induced Arthritis
Endocrine, Metabolic & Immune Disorders - Drug Targets Patent Annotations
Recent Patents on Anti-Infective Drug Discovery Synthesis of pyridyl benzimidazoles encompassing 4-thiazolidinone derivatives as potential antimicrobial agents
Letters in Drug Design & Discovery Lung Transplantation: Perioperative Pharmacology and Anesthetic Considerations
Current Clinical Pharmacology A Perspective on Quantum Mechanics Calculations in ADMET Predictions
Current Topics in Medicinal Chemistry Induced Depressive Disorder Following the First Dose of COVID-19 Vaccine
CNS & Neurological Disorders - Drug Targets The Metabolic Response of Glycogen and Free Fatty Acids to Endurance Exercise
Current Metabolomics Trends in Deep Learning for Property-driven Drug Design
Current Medicinal Chemistry Review: Studies on the Synthesis of Quinolone Derivatives with Their Antibacterial Activity (Part 1)
Current Organic Chemistry An Insight into the Dermatological Applications of Neem: A Review on Traditional and Modern Aspect
Recent Advances in Anti-Infective Drug Discovery Orphan Nuclear Receptor Modulators
Current Topics in Medicinal Chemistry Acronycine Derivatives: A Promising Series of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Microwave-Assisted Synthesis of Some New Benzimidazole Derivatives with their Antimicrobial Activity
Current Microwave Chemistry Desferrioxamine as Immunomodulatory Agent During Microorganism Infection
Current Pharmaceutical Design Advances in Inhibitors of FXa
Current Drug Targets Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical Based Evidence
Current Pharmaceutical Design